Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
This article was originally published in The Pink Sheet Daily
The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.
You may also be interested in...
Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.
Takeda Pharmaceuticals Co. Ltd.'s €9.6 billion ($13.6 billion) purchase of privately held Nycomed AS, confirmed May 19 after a week of speculation, satisfies a number of strategic and financial imperatives for Japan's largest drug maker, as it faces generic competition to best-selling diabetes drug Actos (pioglitazone) from 2012 and seeks to expand its footprint beyond Japan and the U.S.
Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.